Economic evaluation of first-line and maintenance treatments for advanced non-small cell lung cancer: a systematic review

Por Chouaïd, Christos, Crequit, Perinne, Borget, Isabelle, Vergnenegre, Alain
Publicado no Clinicoecon Outcomes Res (2014)

Management of elderly patients

Por Vergnenegre, Alain, Corre, Romain, Lena, Hervé, Le Caer, Hervé
Publicado no Transl Lung Cancer Res (2013)

How old is “too old” for translational research?

Por Vergnenegre, Alain, Corre, Romain, Lena, Hervé, Le Caer, Hervé
Publicado no Transl Lung Cancer Res (2014)

Cross-market cost-effectiveness analysis of erlotinib as first-line maintenance treatment for patients with stable non-small cell lung cancer

Por Vergnenègre, Alain, Ray, Joshua A, Chouaid, Christos, Grossi, Francesco, Bischoff, Helge G, Heigener, David F, Walzer, Stefan
Publicado em 2012

Maintenance erlotinib in advanced nonsmall cell lung cancer: cost-effectiveness in EGFR wild-type across Europe

Por Walleser, Silke, Ray, Joshua, Bischoff, Helge, Vergnenègre, Alain, Rosery, Hubertus, Chouaid, Christos, Heigener, David, de Castro Carpeño, Javier, Tiseo, Marcello, Walzer, Stefan
Publicado em 2012

Cost savings of home bortezomib injection in patients with multiple myeloma treated by a combination care in Outpatient Hospital and Hospital care at Home

Por Touati, Mohamed, Lamarsalle, Ludovic, Moreau, Stéphane, Vergnenègre, Françoise, Lefort, Sophie, Brillat, Catherine, Jeannet, Laetitia, Lagarde, Aline, Daulange, Annick, Jaccard, Arnaud, Vergnenègre, Alain, Bordessoule, Dominique
Publicado no Support Care Cancer (2016)

ROR1 as a novel therapeutic target for EGFR-mutant non-small-cell lung cancer patients with the EGFR T790M mutation

Por Karachaliou, Niki, Gimenez-Capitan, Ana, Drozdowskyj, Ana, Viteri, Santiago, Moran, Teresa, Carcereny, Enric, Massuti, Bartomeu, Vergnenegre, Alain, de Marinis, Filippo, Molina, Miguel Angel, Teixido, Cristina, Rosell, Rafael
Publicado no Transl Lung Cancer Res (2014)

Combinatory effect of BRCA1 and HERC2 expression on outcome in advanced non-small-cell lung cancer

Por Bonanno, Laura, Costa, Carlota, Majem, Margarita, Sanchez, Jose-Javier, Rodriguez, Ignacio, Gimenez-Capitan, Ana, Molina-Vila, Miquel Angel, Vergnenegre, Alain, Massuti, Bartomeu, Favaretto, Adolfo, Rugge, Massimo, Pallares, Cinta, Taron, Miquel, Rosell, Rafael
Publicado no BMC Cancer (2016)

Cost-utility analysis of maintenance therapy with gemcitabine or erlotinib vs observation with predefined second-line treatment after cisplatin–gemcitabine induction chemotherapy f...

Por Borget, Isabelle, Pérol, Maurice, Pérol, David, Lavolé, Armelle, Greillier, Laurent, Dô, Pascal, Westeel, Virginie, Crequit, Jacky, Léna, Hervé, Monnet, Isabelle, Le Caer, Hervé, Fournel, Pierre, Falchero, Lionel, Poudenx, Michel, Vaylet, Fabien, Chabaud, Sylvie, Vergnenegre, Alain, Zalcman, Gérard, Chouaïd, Christos
Publicado no BMC Cancer (2014)

BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer

Por Karachaliou, Niki, Codony-Servat, Jordi, Teixidó, Cristina, Pilotto, Sara, Drozdowskyj, Ana, Codony-Servat, Carles, Giménez-Capitán, Ana, Molina-Vila, Miguel Angel, Bertrán-Alamillo, Jordi, Gervais, Radj, Massuti, Bartomeu, Morán, Teresa, Majem, Margarita, Felip, Enriqueta, Carcereny, Enric, García-Campelo, Rosario, Viteri, Santiago, González-Cao, María, Morales-Espinosa, Daniela, Verlicchi, Alberto, Crisetti, Elisabetta, Chaib, Imane, Santarpia, Mariacarmela, Luis Ramírez, José, Bosch-Barrera, Joaquim, Felipe Cardona, Andrés, de Marinis, Filippo, López-Vivanco, Guillermo, Miguel Sánchez, José, Vergnenegre, Alain, Sánchez Hernández, José Javier, Sperduti, Isabella, Bria, Emilio, Rosell, Rafael
Publicado no Sci Rep (2015)